• Explore /
  • Poster
  • / Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.

Abstract Video & Slides Poster

Authors

null

Thomas Powles

Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, and Queen Mary University of London, London, United Kingdom

Thomas Powles , Elizabeth R. Plimack , Viktor Stus , Tom Waddell , Rustem Gafanov , Frédéric Pouliot , Dmitry Nosov , Bohuslav Melichar , Denis Soulieres , Delphine Borchiellini , Ihor Vynnychenko , Raymond S. McDermott , Sergio Jobim Azevedo , Satoshi Tamada , Anna Kryzhanivska , Chenxiang Li , Joseph E. Burgents , L. Rhoda Molife , Brian I. Rini , Jens Bedke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02853331

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4513)

DOI

10.1200/JCO.2022.40.16_suppl.4513

Abstract #

4513

Poster Bd #

5

Abstract Disclosures

Similar Posters

Poster

2020 Genitourinary Cancers Symposium

Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.

Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.

First Author: Arielle G. Bensimon

First Author: Maria Cruz Martin Soberón

First Author: Yu Fujiwara

First Author: Bradley Alexander McGregor